Skip to content

Pain Control After Orthognathic Surgery

Intra-operative Trigeminal Nerve Block For Post-operative Pain Control After Orthognathic Surgery

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01418183
Acronym
PCOGS
Enrollment
40
Registered
2011-08-17
Start date
2011-07-31
Completion date
2012-12-31
Last updated
2011-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Pain

Keywords

Orthognathic surgery, Pain control, Trigeminal nerve, Levobupivacaine

Brief summary

This study will assess the efficacy and safety of levobupivacaine for postoperative pain control in patients received orthognathic surgery. In this split-mouth study, each side will be randomized to receive 1) 5ml 0.5% levobupivacine, 2) 2.5ml 0.5% levobupivacaine, or 3) placebo. One shot of these agents will be delivered by nerve block to maxillary and mandibular branches of trigeminal nerve before the incision was made. The degree of postoperative pain will be evaluated daily by visual analog scale for up to 3 days. The anticipated time on study is 1 year, and the target sample size is 40 individuals.

Detailed description

Design of intervention vs. control Intra-operative injective of (chirocaine) before incision Location of injection: inferior alveolar nerve proximal to its entrance to ramus of mandible, maxillary nerve around pterygopalatine ganglion Amount of injection on each injection site: (1) Experimental group 1: 5mg/ml chirocaine 5cc (2)Experimental group 2: 5mg/ml chirocaine 2.5cc (3)Control group: normal saline 5cc. There are totally 4 injection sites for two jaw surgery and 2 injection sites for one jaw surgery. The experimental site and control site will be determined randomly before injection. Outcome measurement * Primary: effectiveness of intra-operative nerve block on post-operative pain control * Secondary: 1. whether the pain relieve effect is dose-related 2. how long will this effect last The intensity of post-operative pain will be measured by VAS, visual analog scale)daily until patients are discharged. Report adverse outcome: * Intolerable pain on control group * Adverse reaction to local anesthetic agent * Injection-related complications (puncture of major vessels, hematoma on -injection site, etc.)

Interventions

5ml of long-effective local analgesics (5% levobupivacaine) will be delivered to maxillary and mandibular branches of trigeminal nerve.

Sponsors

Chang Gung Memorial Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* all patients who will receive orthognathic surgery (one jaw or two jaw, with or without genioplasty) in Chang Gung Memorial Hospital since July 2011

Exclusion criteria

* more complex (2- or more piece LeFort I osteotomy, combined gonial resection in BSSO, etc.) or less complex (only Wassmund and/or Kole osteotomies in upper or lower jaw) orthognathic procedures * unexpected fracture (unilateral) * intra-operative nerve injuries * significant facial asymmetry which demands different procedures (location of osteotomy, extension of muscle stripping, etc.) * cleft patient, post-traumatic patients, patients with craniofacial syndromes or other neurological or systemic problems which might interfere pain evaluation post-operatively

Design outcomes

Primary

MeasureTime frameDescription
Postoperative painparticipants will be followed for the duration of hospital stay, an expected average of 3daysThe degree of pain will be measured daily by visual analog scale.

Secondary

MeasureTime frame
Effective duration of levobupivacaine nerve blockparticipants will be followed for the duration of hospital stay, an expected average of 3 days

Countries

Taiwan

Contacts

Primary ContactYi-Chieh Chen, MD
Pschenyc@yahoo.com.tw+886-975-365553

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026